China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Tariff Resilience Score: 0/10 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600062 China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
90 GF Score
Price ¥16.93
GF Value ¥18.81
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China Resources Double-Crane Pharmaceutical Co Tariff Resilience Score?

China Resources Double-Crane Pharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

China Resources Double-Crane Pharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes China Resources Double-Crane Pharmaceutical Co might have .


China Resources Double-Crane Pharmaceutical Co  (SHSE:600062) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

China Resources Double-Crane Pharmaceutical Co Tariff Resilience Score Related Terms

SHSE:600062
90GF Score
China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.93 is trading 10% below its estimated GF Value™ of ¥18.81. GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600062:

  • Tariff Resilience Score: 0
  • GF Value™: ¥18.81 vs. price of ¥16.93 (10% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Resources Double-Crane Pharmaceutical Co Business Description

Address No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score

Get the complete analysis for SHSE:600062

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.93
Price
¥18.81
GF Value